Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

1.

HIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana.

Shapiro RL, Kitch D, Ogwu A, Hughes MD, Lockman S, Powis K, Souda S, Moffat C, Moyo S, McIntosh K, van Widenfelt E, Zwerski S, Mazhani L, Makhema J, Essex M.

AIDS. 2013 Jul 31;27(12):1911-20.

2.

Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.

Shapiro RL, Rossi S, Ogwu A, Moss M, Leidner J, Moffat C, Lockman S, Moyo S, Makhema J, Essex M, Capparelli E.

Antivir Ther. 2013;18(4):585-90. doi: 10.3851/IMP2474. Epub 2012 Nov 26.

PMID:
23183881
3.

Science and ethics of human immunodeficiency virus/acquired immunodeficiency syndrome controversies in Africa.

Brewster D.

J Paediatr Child Health. 2011 Sep;47(9):646-55. doi: 10.1111/j.1440-1754.2011.02179.x.

PMID:
21951451
4.

Increased risk of severe infant anemia after exposure to maternal HAART, Botswana.

Dryden-Peterson S, Shapiro RL, Hughes MD, Powis K, Ogwu A, Moffat C, Moyo S, Makhema J, Essex M, Lockman S.

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):428-36. doi: 10.1097/QAI.0b013e31820bd2b6.

5.

Mother-to-child transmission of HIV-1 in sub-Saharan Africa: past, present and future challenges.

Taha TE.

Life Sci. 2011 May 23;88(21-22):917-21. doi: 10.1016/j.lfs.2010.09.031. Epub 2010 Oct 8. Review.

PMID:
20933522
6.

Antiretroviral regimens in pregnancy and breast-feeding in Botswana.

Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, Makhema J, Moyo S, Thior I, McIntosh K, van Widenfelt E, Leidner J, Powis K, Asmelash A, Tumbare E, Zwerski S, Sharma U, Handelsman E, Mburu K, Jayeoba O, Moko E, Souda S, Lubega E, Akhtar M, Wester C, Tuomola R, Snowden W, Martinez-Tristani M, Mazhani L, Essex M.

N Engl J Med. 2010 Jun 17;362(24):2282-94. doi: 10.1056/NEJMoa0907736.

7.

Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.

Bae WH, Wester C, Smeaton LM, Shapiro RL, Lockman S, Onyait K, Thior I, Essex M.

AIDS. 2008 Aug 20;22(13):1633-40. doi: 10.1097/QAD.0b013e328307a029.

8.

Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.

Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, Heymann SJ, Gilbert PB, Stevens L, Peter T, Kim S, van Widenfelt E, Moffat C, Ndase P, Arimi P, Kebaabetswe P, Mazonde P, Makhema J, McIntosh K, Novitsky V, Lee TH, Marlink R, Lagakos S, Essex M; Mashi Study Team.

JAMA. 2006 Aug 16;296(7):794-805.

PMID:
16905785
9.

Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk.

Shapiro RL, Ndung'u T, Lockman S, Smeaton LM, Thior I, Wester C, Stevens L, Sebetso G, Gaseitsiwe S, Peter T, Essex M.

J Infect Dis. 2005 Sep 1;192(5):713-9. Epub 2005 Jul 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk